Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires
Lab-grown meat, now more commonly referred to as cultivated meat, cell-cultured meat, or cellular agriculture, has evolved from a speculative biotechnology concept into an emerging commercial sector attracting investors, biotechnology companies, food industry leaders, and researchers worldwide.
Produced by expanding animal cells from species such as cattle, pigs, chicken, fish, and other livestock within controlled bioreactor environments, cultivated meat has the potential to reshape portions of the global protein market. Rather than raising and slaughtering animals, cultivated meat companies use cellular agriculture techniques to produce animal-derived tissues directly from cells. [Read more…]
South Korean-based “iPS Bio” Establishes Japanese Subsidiary, Deepening Ties to Japan’s iPSC Ecosystem
A South Korea–based regenerative medicine company, iPS Bio, Inc., is accelerating its international footprint with the establishment of a new Japanese subsidiary in Yokohama, Kanagawa Prefecture. The move reflects a broader trend of cross-border collaboration in the induced pluripotent stem cell (iPSC) sector, particularly between leading innovation hubs in East Asia. [Read more…]
Leading Competitors within the Induced Pluripotent Stem Cell (iPSC) Market
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market
*Sponsored Content: The article is sponsored by Takara Bio.
A few years back, Takara Bio 
announced that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, had granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells were to be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.
This announcement made Takara Bio the first company worldwide to offer this service for human ESCs.
Takara Bio’s Role with Human Pluripotent Stem Cells
The significance of this event is that Takara Bio is capable of providing a predictable and reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities, according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]
- 1
- 2
- 3
- …
- 9
- Next Page »